Australia - English - Department of Health (Therapeutic Goods Administration)

amgen australia pty ltd - darbepoetin alfa, quantity: 100 microgram/ml - injection, solution - excipient ingredients: monobasic sodium phosphate monohydrate; sodium chloride; water for injections; dibasic sodium phosphate; polysorbate 80 - aranesp is indicated for the treatment of anaemia associated with chronic renal failure (crf). aranesp is also indicated for the treatment of anaemia and reduction of transfusion requirements in patients with non-myeloid malignancies where anaemia develops as a result of concomitantly administered chemotherapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

amgen australia pty ltd - darbepoetin alfa, quantity: 100 microgram/ml - injection, solution - excipient ingredients: sodium chloride; polysorbate 80; monobasic sodium phosphate monohydrate; dibasic sodium phosphate; water for injections - aranesp is indicated for the treatment of anaemia associated with chronic renal failure (crf). aranesp is also indicated for the treatment of anaemia and reduction of transfusion requirements in patients with non-myeloid malignancies where anaemia develops as a result of concomitantly administered chemotherapy

Australia - English - Department of Health (Therapeutic Goods Administration)

amgen australia pty ltd - darbepoetin alfa, quantity: 100 microgram/ml - injection, solution - excipient ingredients: monobasic sodium phosphate monohydrate; dibasic sodium phosphate; water for injections; polysorbate 80; sodium chloride - aranesp is indicated for the treatment of anaemia associated with chronic renal failure (crf). aranesp is also indicated for the treatment of anaemia and reduction of transfusion requirements in patients with non-myeloid malignancies where anaemia develops as a result of concomitantly administered chemotherapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

amgen australia pty ltd - darbepoetin alfa, quantity: 40 microgram/ml - injection, solution - excipient ingredients: sodium chloride; monobasic sodium phosphate monohydrate; polysorbate 80; water for injections; dibasic sodium phosphate - aranesp is indicated for the treatment of anaemia associated with chronic renal failure (crf). aranesp is also indicated for the treatment of anaemia and reduction of transfusion requirements in patients with non-myeloid malignancies where anaemia develops as a result of concomitantly administered chemotherapy

Australia - English - Department of Health (Therapeutic Goods Administration)

amgen australia pty ltd - darbepoetin alfa, quantity: 39.47 microgram/ml - injection, solution - excipient ingredients: monobasic sodium phosphate monohydrate; sodium chloride; dibasic sodium phosphate; polysorbate 80; water for injections - aranesp is indicated for the treatment of anaemia associated with chronic renal failure (crf). aranesp is also indicated for the treatment of anaemia and reduction of transfusion requirements in patients with non-myeloid malignancies where anaemia develops as a result of concomitantly administered chemotherapy

Australia - English - Department of Health (Therapeutic Goods Administration)

amgen australia pty ltd - darbepoetin alfa, quantity: 25 microgram/ml - injection, solution - excipient ingredients: water for injections; sodium chloride; dibasic sodium phosphate; polysorbate 80; monobasic sodium phosphate monohydrate - aranesp is indicated for the treatment of anaemia associated with chronic renal failure (crf). aranesp is also indicated for the treatment of anaemia and reduction of transfusion requirements in patients with non-myeloid malignancies where anaemia develops as a result of concomitantly administered chemotherapy

Israel - English - Ministry of Health

amgen europe b.v. - darbepoetin alfa - solution for injection - darbepoetin alfa 10 mcg / 0.4 ml - darbepoetin alfa - aranesp ® is indicated for the treatment of symptomatic anaemia associated with chronic renal failure (crf) in adults and paediatric patients ≥ 1 year of age

Israel - English - Ministry of Health

amgen europe b.v. - darbepoetin alfa - solution for injection - darbepoetin alfa 100 mcg / 0.5 ml - darbepoetin alfa - aranesp ® is indicated for the treatment of symptomatic anaemia associated with chronic renal failure (crf) in adults and paediatric patients ≥ 1 year of age

Israel - English - Ministry of Health

amgen europe b.v. - darbepoetin alfa - solution for injection - darbepoetin alfa 150 mcg / 0.3 ml - darbepoetin alfa - aranesp ® is indicated for the treatment of symptomatic anaemia associated with chronic renal failure (crf) in adults and paediatric patients ≥ 1 year of age.aranesp ® is indicated for the treatment of symptomatic anaemia in adult cancer patients with non-myeloid malignancies receiving chemotherapy.

Israel - English - Ministry of Health

amgen europe b.v. - darbepoetin alfa - solution for injection - darbepoetin alfa 20 mcg / 0.5 ml - darbepoetin alfa - aranesp ® is indicated for the treatment of symptomatic anaemia associated with chronic renal failure (crf) in adults and paediatric patients ≥ 1 year of age